 Michael Handler
Concepts (483)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 28 | 2023 | 987 | 2.730 |
Why?
| | Ependymoma | 15 | 2020 | 157 | 1.780 |
Why?
| | Hydrocephalus | 5 | 2022 | 81 | 1.630 |
Why?
| | Neural Tube Defects | 3 | 2021 | 61 | 1.380 |
Why?
| | Brain Stem Neoplasms | 8 | 2018 | 86 | 1.370 |
Why?
| | Neurosurgical Procedures | 7 | 2023 | 154 | 1.350 |
Why?
| | Decompression, Surgical | 4 | 2022 | 93 | 1.240 |
Why?
| | Neurosurgery | 2 | 2023 | 26 | 1.240 |
Why?
| | Magnetic Resonance Imaging | 18 | 2023 | 3053 | 1.240 |
Why?
| | Arnold-Chiari Malformation | 4 | 2022 | 30 | 1.150 |
Why?
| | Glioma | 7 | 2021 | 296 | 1.140 |
Why?
| | Craniopharyngioma | 8 | 2020 | 65 | 1.030 |
Why?
| | Cerebrospinal Fluid Shunts | 5 | 2017 | 28 | 0.990 |
Why?
| | Spinal Injuries | 2 | 2019 | 48 | 0.980 |
Why?
| | Germinoma | 2 | 2022 | 12 | 0.880 |
Why?
| | Child | 65 | 2023 | 18366 | 0.870 |
Why?
| | Pineal Gland | 1 | 2022 | 13 | 0.820 |
Why?
| | Pinealoma | 1 | 2022 | 11 | 0.820 |
Why?
| | Child, Preschool | 45 | 2019 | 9086 | 0.730 |
Why?
| | Epilepsy | 5 | 2017 | 277 | 0.680 |
Why?
| | Pituitary Neoplasms | 5 | 2020 | 157 | 0.630 |
Why?
| | Meningomyelocele | 4 | 2022 | 55 | 0.620 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2326 | 0.620 |
Why?
| | Skull Neoplasms | 1 | 2017 | 22 | 0.600 |
Why?
| | Medulloblastoma | 6 | 2022 | 172 | 0.590 |
Why?
| | Cerebellar Neoplasms | 5 | 2022 | 131 | 0.580 |
Why?
| | Infant | 35 | 2019 | 7937 | 0.580 |
Why?
| | Sarcoma, Ewing | 1 | 2017 | 65 | 0.560 |
Why?
| | Humans | 105 | 2023 | 114935 | 0.560 |
Why?
| | Gene Expression Regulation, Neoplastic | 13 | 2022 | 1148 | 0.520 |
Why?
| | Colectomy | 1 | 2016 | 86 | 0.500 |
Why?
| | Ventriculoperitoneal Shunt | 3 | 2019 | 30 | 0.490 |
Why?
| | Female | 59 | 2022 | 59580 | 0.490 |
Why?
| | Infratentorial Neoplasms | 4 | 2019 | 46 | 0.490 |
Why?
| | Ganglioglioma | 4 | 2016 | 31 | 0.490 |
Why?
| | Child Abuse | 4 | 2015 | 450 | 0.490 |
Why?
| | Rhabdoid Tumor | 3 | 2013 | 80 | 0.490 |
Why?
| | Gene Expression Profiling | 15 | 2020 | 1523 | 0.480 |
Why?
| | Male | 55 | 2022 | 55663 | 0.480 |
Why?
| | Wounds, Nonpenetrating | 2 | 2019 | 225 | 0.470 |
Why?
| | Reoperation | 2 | 2016 | 515 | 0.470 |
Why?
| | Adolescent | 38 | 2021 | 17829 | 0.470 |
Why?
| | Retrospective Studies | 27 | 2022 | 12544 | 0.470 |
Why?
| | Biomarkers, Tumor | 8 | 2018 | 1054 | 0.470 |
Why?
| | Craniotomy | 2 | 2012 | 67 | 0.460 |
Why?
| | Astrocytoma | 6 | 2013 | 109 | 0.460 |
Why?
| | Cerebral Cortex | 1 | 2017 | 381 | 0.450 |
Why?
| | Pleural Cavity | 1 | 2013 | 2 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2014 | 863 | 0.440 |
Why?
| | Supratentorial Neoplasms | 3 | 2019 | 17 | 0.440 |
Why?
| | Colitis | 1 | 2016 | 226 | 0.440 |
Why?
| | Crohn Disease | 1 | 2016 | 196 | 0.420 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2020 | 686 | 0.420 |
Why?
| | Pons | 4 | 2015 | 30 | 0.410 |
Why?
| | Teratoma | 2 | 2011 | 92 | 0.390 |
Why?
| | Accidents | 1 | 2012 | 38 | 0.390 |
Why?
| | Infant, Newborn | 18 | 2019 | 5035 | 0.370 |
Why?
| | Treatment Outcome | 18 | 2022 | 9105 | 0.370 |
Why?
| | Brain Injuries | 2 | 2015 | 452 | 0.370 |
Why?
| | Cervical Vertebrae | 2 | 2015 | 106 | 0.350 |
Why?
| | Head Injuries, Closed | 1 | 2010 | 48 | 0.350 |
Why?
| | Central Nervous System | 2 | 2014 | 238 | 0.340 |
Why?
| | Membrane Proteins | 3 | 2012 | 1022 | 0.330 |
Why?
| | Prognosis | 16 | 2019 | 3344 | 0.330 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2017 | 193 | 0.320 |
Why?
| | Postoperative Complications | 6 | 2022 | 2133 | 0.320 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 67 | 0.310 |
Why?
| | Syringomyelia | 2 | 2011 | 11 | 0.300 |
Why?
| | Cerebrospinal Fluid | 2 | 2007 | 90 | 0.300 |
Why?
| | Oligonucleotide Array Sequence Analysis | 12 | 2016 | 744 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 1361 | 0.300 |
Why?
| | Intracranial Hemorrhages | 2 | 2015 | 76 | 0.300 |
Why?
| | Spinal Cord Neoplasms | 3 | 2009 | 38 | 0.290 |
Why?
| | RNA, Messenger | 9 | 2017 | 2558 | 0.280 |
Why?
| | Transcriptome | 5 | 2022 | 728 | 0.280 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 2725 | 0.270 |
Why?
| | Vancomycin | 1 | 2007 | 75 | 0.260 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.260 |
Why?
| | Chloroquine | 2 | 2017 | 52 | 0.250 |
Why?
| | Proto-Oncogene Proteins | 3 | 2016 | 611 | 0.250 |
Why?
| | Cerebral Hemorrhage | 2 | 2017 | 96 | 0.240 |
Why?
| | Immunophenotyping | 2 | 2017 | 277 | 0.240 |
Why?
| | Glioblastoma | 4 | 2013 | 253 | 0.240 |
Why?
| | Intraoperative Complications | 2 | 1996 | 122 | 0.240 |
Why?
| | Laparoscopy | 1 | 2008 | 389 | 0.240 |
Why?
| | Adult | 22 | 2020 | 30608 | 0.230 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 978 | 0.230 |
Why?
| | Neurosurgeons | 1 | 2023 | 13 | 0.220 |
Why?
| | Nuclear Proteins | 3 | 2017 | 593 | 0.220 |
Why?
| | Autophagy | 2 | 2017 | 234 | 0.220 |
Why?
| | Indoles | 2 | 2017 | 306 | 0.220 |
Why?
| | Tumor Suppressor Proteins | 3 | 2017 | 282 | 0.220 |
Why?
| | Spinal Neoplasms | 1 | 2003 | 30 | 0.220 |
Why?
| | Cell Proliferation | 8 | 2019 | 2199 | 0.210 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.210 |
Why?
| | Electroencephalography | 4 | 2018 | 362 | 0.210 |
Why?
| | Osteosarcoma | 1 | 2003 | 67 | 0.210 |
Why?
| | Narcotics | 1 | 2022 | 44 | 0.200 |
Why?
| | Combined Modality Therapy | 7 | 2015 | 1126 | 0.200 |
Why?
| | Cell Cycle Proteins | 3 | 2016 | 552 | 0.200 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.200 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2022 | 35 | 0.200 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 180 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 1897 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| | SEER Program | 4 | 2018 | 196 | 0.190 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 190 | 0.190 |
Why?
| | Scoliosis | 2 | 2011 | 179 | 0.190 |
Why?
| | Lumbosacral Region | 1 | 2021 | 46 | 0.190 |
Why?
| | Parietal Bone | 1 | 2000 | 11 | 0.190 |
Why?
| | Transcription Factor RelA | 2 | 2019 | 83 | 0.180 |
Why?
| | Connective Tissue | 1 | 2000 | 36 | 0.180 |
Why?
| | Skull Fractures | 1 | 2000 | 29 | 0.180 |
Why?
| | Epilepsies, Partial | 2 | 2018 | 29 | 0.180 |
Why?
| | Inclusion Bodies | 2 | 2012 | 24 | 0.180 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 64 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 59 | 0.170 |
Why?
| | Data Collection | 2 | 2014 | 623 | 0.170 |
Why?
| | Biopsy | 3 | 2018 | 1045 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 929 | 0.170 |
Why?
| | Prenatal Care | 2 | 2022 | 255 | 0.170 |
Why?
| | Obstetric Surgical Procedures | 1 | 2019 | 5 | 0.170 |
Why?
| | Follow-Up Studies | 7 | 2018 | 4427 | 0.170 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 265 | 0.170 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 12 | 0.160 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.160 |
Why?
| | Fetal Therapies | 1 | 2019 | 30 | 0.160 |
Why?
| | Maternal Health | 1 | 2019 | 41 | 0.160 |
Why?
| | Pteridines | 2 | 2016 | 20 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 189 | 0.160 |
Why?
| | Astrocytes | 2 | 2012 | 162 | 0.160 |
Why?
| | Neuroblastoma | 1 | 2019 | 132 | 0.160 |
Why?
| | Microarray Analysis | 5 | 2017 | 119 | 0.150 |
Why?
| | Hysterotomy | 1 | 2017 | 10 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2017 | 23 | 0.150 |
Why?
| | Cyst Fluid | 1 | 2017 | 27 | 0.150 |
Why?
| | Fetoscopy | 1 | 2017 | 28 | 0.150 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.150 |
Why?
| | Drug Resistant Epilepsy | 1 | 2018 | 45 | 0.140 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2018 | 121 | 0.140 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 305 | 0.140 |
Why?
| | Chordoma | 1 | 2017 | 12 | 0.140 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 25 | 0.140 |
Why?
| | Meningioma | 1 | 2018 | 78 | 0.140 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 36 | 0.140 |
Why?
| | Equipment Failure | 2 | 2013 | 107 | 0.140 |
Why?
| | Young Adult | 12 | 2021 | 10478 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 88 | 0.140 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 138 | 0.140 |
Why?
| | Neuroimaging | 1 | 2019 | 248 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2017 | 642 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2012 | 385 | 0.140 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.140 |
Why?
| | Electrocoagulation | 1 | 1996 | 38 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2017 | 140 | 0.140 |
Why?
| | Tissue Banks | 1 | 2016 | 18 | 0.140 |
Why?
| | Electrodes, Implanted | 1 | 2017 | 91 | 0.140 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 38 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 142 | 0.130 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.130 |
Why?
| | Myeloid Cells | 2 | 2015 | 128 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2019 | 352 | 0.130 |
Why?
| | Algorithms | 2 | 2020 | 1474 | 0.130 |
Why?
| | Zoonoses | 1 | 2015 | 21 | 0.130 |
Why?
| | Risk Factors | 7 | 2019 | 8637 | 0.130 |
Why?
| | Ketorolac | 1 | 2015 | 16 | 0.130 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.130 |
Why?
| | MicroRNAs | 2 | 2012 | 601 | 0.130 |
Why?
| | Survivors | 2 | 2023 | 411 | 0.130 |
Why?
| | Cohort Studies | 8 | 2021 | 4903 | 0.130 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 15 | 0.130 |
Why?
| | Dog Diseases | 1 | 2015 | 41 | 0.130 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 19 | 0.120 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
| | Temporal Lobe | 1 | 2015 | 79 | 0.120 |
Why?
| | Receptor, ErbB-3 | 1 | 2015 | 41 | 0.120 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 39 | 0.120 |
Why?
| | Recurrence | 2 | 2016 | 937 | 0.120 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 224 | 0.120 |
Why?
| | Lumbar Vertebrae | 1 | 2016 | 211 | 0.120 |
Why?
| | Cytokines | 3 | 2017 | 1843 | 0.120 |
Why?
| | Ventriculostomy | 1 | 1994 | 17 | 0.120 |
Why?
| | src-Family Kinases | 1 | 2015 | 88 | 0.120 |
Why?
| | Endoscopes | 1 | 1994 | 18 | 0.120 |
Why?
| | Encephalitis | 1 | 2016 | 127 | 0.120 |
Why?
| | Perioperative Care | 1 | 2015 | 126 | 0.120 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1180 | 0.120 |
Why?
| | Radiation Tolerance | 2 | 2012 | 92 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 5 | 2016 | 817 | 0.120 |
Why?
| | Accidents, Traffic | 2 | 2012 | 167 | 0.110 |
Why?
| | Time Factors | 4 | 2019 | 6125 | 0.110 |
Why?
| | NF-kappa B | 1 | 2017 | 637 | 0.110 |
Why?
| | Pediatrics | 1 | 2021 | 984 | 0.110 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 174 | 0.110 |
Why?
| | Professional Practice | 1 | 2014 | 62 | 0.110 |
Why?
| | Blotting, Western | 3 | 2014 | 1151 | 0.110 |
Why?
| | Brain | 2 | 2023 | 2372 | 0.110 |
Why?
| | Foreign-Body Migration | 1 | 2013 | 37 | 0.110 |
Why?
| | Catheters | 1 | 2013 | 65 | 0.110 |
Why?
| | Central Nervous System Neoplasms | 1 | 2015 | 126 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 115 | 0.110 |
Why?
| | Prevalence | 2 | 2016 | 2252 | 0.110 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 523 | 0.110 |
Why?
| | Kidney Neoplasms | 2 | 2017 | 334 | 0.110 |
Why?
| | B7 Antigens | 1 | 2012 | 9 | 0.110 |
Why?
| | Survival Analysis | 3 | 2014 | 1220 | 0.110 |
Why?
| | Neurology | 1 | 2014 | 84 | 0.110 |
Why?
| | Spinal Dysraphism | 1 | 2013 | 42 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 299 | 0.100 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2012 | 16 | 0.100 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 2012 | 12 | 0.100 |
Why?
| | Lipase | 1 | 2012 | 57 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 296 | 0.100 |
Why?
| | Persistent Vegetative State | 1 | 2012 | 4 | 0.100 |
Why?
| | Seizures | 1 | 2015 | 340 | 0.100 |
Why?
| | Incidence | 3 | 2017 | 2316 | 0.100 |
Why?
| | Cell Survival | 4 | 2017 | 1022 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2013 | 1635 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2015 | 561 | 0.100 |
Why?
| | Rubinstein-Taybi Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
| | Body Mass Index | 1 | 2019 | 1961 | 0.100 |
Why?
| | Glasgow Coma Scale | 1 | 2012 | 144 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2015 | 676 | 0.090 |
Why?
| | Disabled Children | 1 | 2012 | 69 | 0.090 |
Why?
| | Neurologic Examination | 1 | 2011 | 114 | 0.090 |
Why?
| | Cerebellum | 1 | 2012 | 200 | 0.090 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 132 | 0.090 |
Why?
| | Heart Arrest | 1 | 1994 | 289 | 0.090 |
Why?
| | Radiosurgery | 1 | 2014 | 303 | 0.090 |
Why?
| | Sex Factors | 1 | 2016 | 1721 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 334 | 0.090 |
Why?
| | DNA Methylation | 2 | 2021 | 496 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3549 | 0.090 |
Why?
| | Fatty Liver | 1 | 2012 | 213 | 0.090 |
Why?
| | Transcription Factors | 2 | 2017 | 1530 | 0.090 |
Why?
| | Morbidity | 2 | 2018 | 277 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2013 | 344 | 0.090 |
Why?
| | Phenotype | 2 | 2015 | 2817 | 0.090 |
Why?
| | Societies, Medical | 1 | 2014 | 677 | 0.090 |
Why?
| | Surgeons | 1 | 2014 | 237 | 0.090 |
Why?
| | Anilides | 1 | 2010 | 67 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1749 | 0.090 |
Why?
| | Medical Futility | 1 | 2010 | 19 | 0.090 |
Why?
| | Apoptosis | 5 | 2019 | 2371 | 0.090 |
Why?
| | Patient Discharge | 1 | 2016 | 769 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4635 | 0.090 |
Why?
| | United States | 6 | 2019 | 12211 | 0.080 |
Why?
| | Quality of Life | 2 | 2015 | 2359 | 0.080 |
Why?
| | Survival Rate | 4 | 2019 | 1644 | 0.080 |
Why?
| | Electrolytes | 1 | 2009 | 55 | 0.080 |
Why?
| | Pediatric Nursing | 1 | 2009 | 39 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 30 | 0.080 |
Why?
| | Claudins | 1 | 2009 | 24 | 0.080 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2009 | 51 | 0.080 |
Why?
| | Radiotherapy Dosage | 1 | 2009 | 245 | 0.080 |
Why?
| | Obesity | 2 | 2019 | 2514 | 0.080 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 80 | 0.080 |
Why?
| | Medical Records | 1 | 2009 | 154 | 0.080 |
Why?
| | Contractile Proteins | 1 | 2008 | 16 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 1893 | 0.080 |
Why?
| | Sodium | 1 | 2009 | 182 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 171 | 0.080 |
Why?
| | Prospective Studies | 4 | 2019 | 6218 | 0.080 |
Why?
| | Middle Aged | 9 | 2020 | 26806 | 0.080 |
Why?
| | Salvage Therapy | 1 | 2009 | 127 | 0.080 |
Why?
| | Fluid Therapy | 1 | 2009 | 122 | 0.080 |
Why?
| | Point Mutation | 1 | 2009 | 217 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 174 | 0.080 |
Why?
| | Recovery of Function | 1 | 2012 | 572 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 243 | 0.070 |
Why?
| | Catheterization | 1 | 2008 | 160 | 0.070 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2014 | 316 | 0.070 |
Why?
| | Microfilament Proteins | 1 | 2008 | 127 | 0.070 |
Why?
| | Consensus | 1 | 2010 | 534 | 0.070 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 18 | 0.070 |
Why?
| | Pyrimidines | 1 | 2010 | 378 | 0.070 |
Why?
| | DNA Modification Methylases | 1 | 2007 | 14 | 0.070 |
Why?
| | Vertebral Artery | 1 | 2007 | 27 | 0.070 |
Why?
| | Autopsy | 2 | 2012 | 85 | 0.070 |
Why?
| | DNA Repair Enzymes | 1 | 2007 | 22 | 0.070 |
Why?
| | Disease Progression | 3 | 2012 | 2392 | 0.070 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2007 | 68 | 0.070 |
Why?
| | Dacarbazine | 1 | 2007 | 101 | 0.070 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 104 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2009 | 230 | 0.070 |
Why?
| | Colorado | 2 | 2019 | 4091 | 0.070 |
Why?
| | Proteomics | 1 | 2012 | 844 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2007 | 140 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 372 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 880 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 529 | 0.060 |
Why?
| | Athletic Injuries | 1 | 2012 | 456 | 0.060 |
Why?
| | Cell Cycle | 3 | 2014 | 544 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 855 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 434 | 0.060 |
Why?
| | Pregnancy | 4 | 2022 | 5527 | 0.060 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 177 | 0.060 |
Why?
| | Signal Transduction | 2 | 2015 | 4524 | 0.060 |
Why?
| | Age Factors | 3 | 2019 | 2891 | 0.060 |
Why?
| | Drug Synergism | 2 | 2017 | 316 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2019 | 706 | 0.060 |
Why?
| | Gene Expression | 4 | 2015 | 1422 | 0.060 |
Why?
| | Thoracic Vertebrae | 2 | 2003 | 71 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2009 | 685 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2016 | 623 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.060 |
Why?
| | Bleomycin | 2 | 2009 | 228 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2023 | 59 | 0.060 |
Why?
| | Palliative Care | 1 | 2010 | 640 | 0.060 |
Why?
| | Twins, Conjoined | 1 | 2003 | 4 | 0.060 |
Why?
| | Stereotaxic Techniques | 1 | 2003 | 29 | 0.050 |
Why?
| | Survival | 1 | 2003 | 37 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 67 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1355 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 812 | 0.050 |
Why?
| | Mice | 5 | 2022 | 14935 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1440 | 0.050 |
Why?
| | Animals | 7 | 2022 | 31837 | 0.050 |
Why?
| | Conservative Treatment | 1 | 2022 | 29 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 45 | 0.050 |
Why?
| | Vitamin K Deficiency | 1 | 2000 | 10 | 0.050 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2000 | 30 | 0.050 |
Why?
| | Databases, Factual | 2 | 2016 | 1125 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 173 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1080 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 159 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 114 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2013 | 460 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 103 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 2975 | 0.040 |
Why?
| | Herpes Simplex | 1 | 2000 | 87 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2000 | 285 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 4407 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2018 | 6364 | 0.040 |
Why?
| | Diseases in Twins | 1 | 2000 | 174 | 0.040 |
Why?
| | Spinal Fusion | 1 | 2002 | 210 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 913 | 0.040 |
Why?
| | Perinatal Death | 1 | 2019 | 22 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 1999 | 109 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 320 | 0.040 |
Why?
| | DNA, Antisense | 1 | 1998 | 3 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2019 | 38 | 0.040 |
Why?
| | Cysts | 1 | 1999 | 93 | 0.040 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 1998 | 22 | 0.040 |
Why?
| | Stroke | 1 | 2007 | 1019 | 0.040 |
Why?
| | Radiotherapy, Conformal | 1 | 2019 | 68 | 0.040 |
Why?
| | Heparitin Sulfate | 1 | 1998 | 39 | 0.040 |
Why?
| | Mutation | 3 | 2014 | 3353 | 0.040 |
Why?
| | Hemispherectomy | 1 | 2018 | 3 | 0.040 |
Why?
| | Brain Diseases | 1 | 1999 | 125 | 0.040 |
Why?
| | Fetus | 1 | 2022 | 701 | 0.040 |
Why?
| | Radiography | 1 | 2000 | 819 | 0.040 |
Why?
| | Proteoglycans | 1 | 1998 | 107 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 561 | 0.040 |
Why?
| | Vincristine | 1 | 1998 | 100 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 78 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 1998 | 152 | 0.040 |
Why?
| | Carboplatin | 1 | 1998 | 135 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| | Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 34 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 29 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.040 |
Why?
| | Rhabdomyoma | 1 | 2017 | 9 | 0.040 |
Why?
| | Angiomyolipoma | 1 | 2017 | 17 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 1998 | 162 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 718 | 0.040 |
Why?
| | Headache | 1 | 1998 | 132 | 0.040 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 79 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 106 | 0.040 |
Why?
| | Carcinoma | 2 | 2014 | 199 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 269 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 1998 | 181 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 516 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 1998 | 283 | 0.030 |
Why?
| | Heart Neoplasms | 1 | 2017 | 49 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 126 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 435 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 47 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 759 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 531 | 0.030 |
Why?
| | Urea | 1 | 2016 | 68 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 305 | 0.030 |
Why?
| | Genotype | 2 | 2012 | 1775 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 91 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 737 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 337 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 21 | 0.030 |
Why?
| | Cats | 1 | 2015 | 205 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 530 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 347 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 156 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 263 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 82 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 337 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 721 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 357 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 74 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 517 | 0.030 |
Why?
| | Cost of Illness | 1 | 2015 | 254 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 729 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 67 | 0.030 |
Why?
| | Pyrazoles | 1 | 2016 | 364 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1133 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 248 | 0.030 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 130 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.030 |
Why?
| | Argonaute Proteins | 1 | 2012 | 28 | 0.030 |
Why?
| | Exons | 1 | 2013 | 302 | 0.030 |
Why?
| | Kansas | 1 | 2012 | 29 | 0.030 |
Why?
| | Aged | 3 | 2018 | 19122 | 0.030 |
Why?
| | Missouri | 1 | 2012 | 62 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2012 | 37 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2012 | 36 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 635 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 220 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1844 | 0.030 |
Why?
| | Monocytes | 1 | 2015 | 504 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 129 | 0.030 |
Why?
| | Hyalin | 1 | 2012 | 5 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2015 | 476 | 0.020 |
Why?
| | Carbonic Anhydrases | 1 | 2012 | 13 | 0.020 |
Why?
| | Resuscitation | 1 | 1994 | 247 | 0.020 |
Why?
| | Catalase | 1 | 2012 | 117 | 0.020 |
Why?
| | CREB-Binding Protein | 1 | 2011 | 27 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 115 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 445 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 314 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1572 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2012 | 228 | 0.020 |
Why?
| | Gastrostomy | 1 | 2011 | 89 | 0.020 |
Why?
| | Aurora Kinases | 1 | 2010 | 28 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1317 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 2011 | 211 | 0.020 |
Why?
| | Aurora Kinase A | 1 | 2010 | 52 | 0.020 |
Why?
| | Physical Examination | 1 | 2011 | 220 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2017 | 762 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2009 | 7 | 0.020 |
Why?
| | Hypernatremia | 1 | 2009 | 7 | 0.020 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2009 | 10 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 441 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 368 | 0.020 |
Why?
| | KRIT1 Protein | 1 | 2009 | 6 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2012 | 245 | 0.020 |
Why?
| | Hyponatremia | 1 | 2009 | 37 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 802 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 696 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 752 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 867 | 0.020 |
Why?
| | Filamins | 1 | 2008 | 19 | 0.020 |
Why?
| | Cell Division | 1 | 2010 | 759 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 372 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2008 | 135 | 0.020 |
Why?
| | Fibrous Dysplasia, Monostotic | 1 | 1987 | 1 | 0.020 |
Why?
| | Fibrous Dysplasia of Bone | 1 | 1987 | 5 | 0.020 |
Why?
| | Gene Frequency | 1 | 2009 | 481 | 0.020 |
Why?
| | Radiotherapy | 1 | 2009 | 176 | 0.020 |
Why?
| | Spinal Diseases | 1 | 1987 | 44 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2007 | 110 | 0.020 |
Why?
| | Etoposide | 1 | 2007 | 148 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 157 | 0.020 |
Why?
| | Gene Silencing | 1 | 2007 | 172 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1856 | 0.020 |
Why?
| | RNA | 1 | 2012 | 810 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2007 | 221 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2223 | 0.010 |
Why?
| | Anticoagulants | 1 | 2007 | 547 | 0.010 |
Why?
| | Instillation, Drug | 1 | 1999 | 9 | 0.010 |
Why?
| | Injections, Intralesional | 1 | 1999 | 32 | 0.010 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 1998 | 16 | 0.010 |
Why?
| | Fibroblast Growth Factor 10 | 1 | 1998 | 24 | 0.010 |
Why?
| | Growth Substances | 1 | 1998 | 137 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1998 | 83 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1998 | 232 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 1998 | 89 | 0.010 |
Why?
| | Aging | 1 | 1988 | 1621 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 1998 | 222 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 1897 | 0.010 |
Why?
| | Body Height | 1 | 1988 | 180 | 0.000 |
Why?
|
|
Handler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|